GammaCan International to Present at the PIPEs Conference 2006 in New York City
06 November 2006 - 11:30PM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers,
today announced that it will participate at the PIPEs Conference
2006 being held in New York City at The Waldorf - Astoria Hotel on
November 7th and 8th. GammaCan will present on Tuesday, November
7th at 12PM, 1:30PM and 4:30PM all EST. GammaCan's Chief Executive
Officer, Patrick Schnegelsberg, will provide a company overview
along with highlights on recent progress with VitiGam, GammaCan's
lead program under development to treat stage III and IV melanoma
and an update on the GCAN 101 Phase II trial. About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan
plans on having VitiGam to enter phase I/II testing under a US IND
in the near future after it recently held a pre-IND meeting with
the FDA. VitiGam is being designed to target metastatic melanoma
patients with Stage III and IV melanoma. VitiGam is an IgG product
that is different from standard IgGs: It is manufactured from the
plasma of donors with vitiligo, a benign autoimmune skin condition
affecting up to 2% of the general population. GammaCan scientists
have shown that this "enriched" vitiligo IgG (VitiGam) contains
potent anti-melanoma activity in both in vitro and mouse xenograft
melanoma models. Thus, GammaCan expects VitiGam to provide (1)
anti-melanoma activity directed specifically against malignant
melanoma cells and (2) non-specific anti-cancer activity - as is
the case with IgG in general. About GammaCan: GammaCan is focusing
on the commercialization of an innovative anti-cancer immunotherapy
to treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar. GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers,
today announced that it will participate at the PIPEs Conference
2006 being held in New York City at The Waldorf - Astoria Hotel on
November 7th and 8th. GammaCan will present on Tuesday, November
7th at 12PM, 1:30PM and 4:30PM all EST. GammaCan's Chief Executive
Officer, Patrick Schnegelsberg, will provide a company overview
along with highlights on recent progress with VitiGam, GammaCan's
lead program under development to treat stage III and IV melanoma
and an update on the GCAN 101 Phase II trial. About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan
plans on having VitiGam to enter phase I/II testing under a US IND
in the near future after it recently held a pre-IND meeting with
the FDA. VitiGam is being designed to target metastatic melanoma
patients with Stage III and IV melanoma. VitiGam is an IgG product
that is different from standard IgGs: It is manufactured from the
plasma of donors with vitiligo, a benign autoimmune skin condition
affecting up to 2% of the general population. GammaCan scientists
have shown that this "enriched" vitiligo IgG (VitiGam) contains
potent anti-melanoma activity in both in vitro and mouse xenograft
melanoma models. Thus, GammaCan expects VitiGam to provide (1)
anti-melanoma activity directed specifically against malignant
melanoma cells and (2) non-specific anti-cancer activity - as is
the case with IgG in general. About GammaCan: GammaCan is focusing
on the commercialization of an innovative anti-cancer immunotherapy
to treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024